Triad ImmunologiesLLC, & Researchers at U.C. San Diego, Cancer Center<br />Hyperthermia & Dendritic Cell Vaccine for Melan...
Fastest-Growing  Cancer, increasing 10%/year, incidence now 1 on 45 Americans<br />52,000 U.S. Cases, 8,100 deaths (2007)<...
Cancer Vaccines therapeutic vs. preventative “ounce of prevention=pound of cure”<br />Many types showed promise in models;...
Most cancer antigens seen as “self” vs. “germ”<br />Cancer cells hide from immune system using eight different mechanisms ...
Mosquito-borne tropical virus infecting millions per year<br />Only virus where second infection carries higher risk than ...
Specialized white blood cells can program killer cells to attack tumor antigens<br /> Made in 5-7 days from 1 unit of whol...
Combination of 2 biologics tested separately on hundreds of human volunteers<br />Designed to kill 50% of cancer by fever,...
Dr. Boris Minev, M.D., Chief Science Officer<br />Project Scientist, UC San Diego Cancer Center<br />Formerly with Dr. Ste...
Personalized therapy approach complex, but addresses mutation problems.<br />3-5 Outpatient procedures, 1 week hospital.<b...
IND Application 90% complete<br />UCSD mouse models show safety/efficacy<br />Triad owns virus, Carlsbad firm will supply....
Upcoming SlideShare
Loading in …5
×

C:\Users\Aaron\Desktop\Business Power Point 8 12 09

561 views

Published on

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
561
On SlideShare
0
From Embeds
0
Number of Embeds
1
Actions
Shares
0
Downloads
5
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

C:\Users\Aaron\Desktop\Business Power Point 8 12 09

  1. 1. Triad ImmunologiesLLC, & Researchers at U.C. San Diego, Cancer Center<br />Hyperthermia & Dendritic Cell Vaccine for Melanoma<br />
  2. 2. Fastest-Growing Cancer, increasing 10%/year, incidence now 1 on 45 Americans<br />52,000 U.S. Cases, 8,100 deaths (2007)<br />10% 5-year Survival for advanced patients<br />No effective treatment except surgery<br />FDA says new therapies needed now<br />Worldwide therapeutics market of $500 million (2007), reflects lack of efficacy vs. potential ($2 billion)<br />Melanoma Therapeutics Market<br />
  3. 3. Cancer Vaccines therapeutic vs. preventative “ounce of prevention=pound of cure”<br />Many types showed promise in models; failure in clinical trials on Stage IV patients<br />FDA requires testing on advanced patients with lowered immune status<br />Complex, often individualized drug formulations require special handling<br />Lack of immune activation major drawback<br />Cancer Vaccines<br />
  4. 4. Most cancer antigens seen as “self” vs. “germ”<br />Cancer cells hide from immune system using eight different mechanisms to escape<br />Most cases of spontaneous regression occur after high fever during systemic infection<br />Infection can activate immune system to ID and destroy all cells with abnormal antigens<br />Triad’s approach addresses all these factors<br />Immune Activation<br />
  5. 5. Mosquito-borne tropical virus infecting millions per year<br />Only virus where second infection carries higher risk than first- 1 in 2,500 vs. 1 in 60,000, 3X safer than common cold virus<br />Fever of 103.5-105 can kill 50% of tumor cells by shutting down blood flow<br />Hyper-activation of immune system can be harnessed to activate killer cells to eliminate the remaining tumor cells<br />Dengue Fever Virus Type 2 <br />
  6. 6. Specialized white blood cells can program killer cells to attack tumor antigens<br /> Made in 5-7 days from 1 unit of whole blood<br />1 DC can program 3,000 killer cells<br />Low toxicity, these are patient’s own cells<br />Dendreon’sProvenge lacks immune activation, but will likely get FDA approval<br />Dendritic Cell Vaccines<br />
  7. 7. Combination of 2 biologics tested separately on hundreds of human volunteers<br />Designed to kill 50% of cancer by fever, then use billions of killer cells to eliminate the rest<br />Engineered to defeat all 8 known tumor immune evasion methods<br />Employs 6 ways to kill tumor cells in synergy<br />Requires hospital stay of 1-2 weeks<br />CT scans allow assessment at 45 days<br />Summary of Therapy<br />
  8. 8. Dr. Boris Minev, M.D., Chief Science Officer<br />Project Scientist, UC San Diego Cancer Center<br />Formerly with Dr. Steven Rosenberg of NCI-Bethesda, Melanoma Immunotherapy group<br />Dr. Greg Daniels, M.D., Ph.D. ,(Immunology),<br />Clinical Investigator, U.C. San Diego Cancer Center, formerly with Mayo Clinic, MN.<br />Principal Investigators <br />
  9. 9. Personalized therapy approach complex, but addresses mutation problems.<br />3-5 Outpatient procedures, 1 week hospital.<br />Dendreon’sProvenge DC vaccine for Prostate Cancer slated for FDA licensure in 4Q 2009, but lacks any immune activation steps.<br />Virus produced along standard vaccine lines<br />Dendritics produced in 5-7 days, barcoded and shipped Fedex, sterility tested twice.<br />Franchise options to hospitals/clinics.<br />Triad’s Business Model<br />
  10. 10. IND Application 90% complete<br />UCSD mouse models show safety/efficacy<br />Triad owns virus, Carlsbad firm will supply.<br />Estimated time from funding to Phase I-II initiation-6 months<br />U.S. Patent # 6,524,587 “Hyperthermia & Immunotherapy for Leukemias. Lymphomas, and Solid Tumors”, issued Feb. 25, 2003<br />Patent covers use of dengue virus to treat any cancer type, with a potential U.S. Market of $55 billion (2007)<br />Progress To IND/Intellectual Rights <br />

×